Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

88
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
88
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

63
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
63
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

803
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
803

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis.

Circulation research·2026
Same author

Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.

Circulation·2025
Same author

PATCH (Preferred Attachment Strategy for Optimal Electrocardiograms)-1 Study.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

Systolic Blood Pressure, Cardiovascular Health, and Neurocognition in Adolescents.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management.

Journal of thrombosis and thrombolysis·2024
Same author

The journal of thrombosis and thrombolysis: commemorating the written word in science and medicine: three decades and counting.

Journal of thrombosis and thrombolysis·2024

Related Experiment Video

Updated: Nov 5, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K

Factor Xa inhibitors: critical considerations for clinical development and testing.

Richard C Becker1

  • 1University of Cincinnati Heart, Lung and Vascular Institute, 231 Albert Sabin Way, Cincinnati, OH, 45267, USA. Richard.becker@uc.edu.

Journal of Thrombosis and Thrombolysis
|May 15, 2021
PubMed
Summary

Targeting activated Factor X (FXa) with direct oral inhibitors offers a strategy for preventing and treating thrombosis. This approach aims for predictable, safe, and effective anticoagulation in diverse patient groups.

Keywords:
Direct factor Xa inhibitorsDirect oral anticoagulantsFactor X

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.3K

Related Experiment Videos

Last Updated: Nov 5, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.3K

Area of Science:

  • Coagulation biochemistry
  • Hemostasis and thrombosis research
  • Pharmacological targeting of proteases

Background:

  • Thrombotic conditions necessitate effective anticoagulation strategies.
  • Factor Xa (FXa) plays a crucial role in the coagulation cascade.
  • Understanding cellular interactions in coagulation is key to developing targeted therapies.

Purpose of the Study:

  • To develop direct oral inhibitors of Factor Xa (FXa).
  • To achieve rapid, selective, predictable, safe, and effective anticoagulation.
  • To provide therapeutic benefits across a broad patient population.

Main Methods:

  • Leveraging knowledge of coagulation biochemistry.
  • Analyzing sequential steps on tissue factor-bearing cells.
  • Investigating interactions between coagulation proteins, platelets, and inflammatory cells.

Main Results:

  • Successful development of direct oral FXa inhibitors.
  • Demonstrated potential for rapid and selective anticoagulation.
  • Established a foundation for predictable and safe anticoagulant therapy.

Conclusions:

  • Targeted inhibition of FXa is a viable strategy for anticoagulation.
  • Direct oral FXa inhibitors represent advancements in thrombotic condition management.
  • Translational research and public-private collaboration drive therapeutic innovation.